Home / Business and Economy / Merit Medical's Strongest Growth in 3 Years
Merit Medical's Strongest Growth in 3 Years
1 Aug
Summary
- Second-quarter revenue reached $418.8 million, a 10% year-over-year increase.
- Organic growth hit its highest quarterly level in three years.
- Acquired businesses, BioLife and C2 CryoBalloon, exceeded expectations.
Merit Medical Systems announced its second-quarter 2026 financial results on August 1, 2026, revealing a 10% GAAP revenue increase to $418.8 million. This performance represents the company's most robust quarterly organic growth in three years. Constant-currency revenue surpassed prior outlook projections.
The strong revenue growth was attributed to broad-based demand across both Foundational and Therapeutic product segments. Acquisitions, including BioLife and C2 CryoBalloon, significantly contributed to the results, with both businesses exceeding internal expectations during the quarter. President and CEO Martha Aronson expressed pleasure with the company's performance.
Total revenue saw a $33.4 million increase, with U.S. sales rising 12% and international sales growing 5%. Foundational Products revenue increased by 6%, while Therapeutic Products revenue saw a 14% rise. Organically, Foundational Products grew 7.8% and Therapeutic Products expanded by 11.7%, driven by cardiac therapies, endoscopy, and vascular interventions.
